Atea Pharmaceuticals earnings were -$139.5M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest AVIR earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$34.3M, up 2.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, AVIR reported annual earnings of -$168.4M, with 23.9% growth.
Atea Pharmaceuticals Earnings Reports & History FAQ
What were Atea Pharmaceuticals's earnings last quarter?
Atea Pharmaceuticals (NASDAQ: AVIR) reported Q1 2025 earnings per share (EPS) of -$0.40, up 46.67% year over year. Total AVIR earnings for the quarter were -$34.27 million. In the same quarter last year, Atea Pharmaceuticals's earnings per share (EPS) was -$0.75.
Is Atea Pharmaceuticals profitable or losing money?
As of the last Atea Pharmaceuticals earnings report, Atea Pharmaceuticals is currently losing money. Atea Pharmaceuticals's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$139.49 million, a 14.77% decrease year over year.
What was AVIR's earnings growth in the past year?
As of Atea Pharmaceuticals's earnings date in Q2 2025, Atea Pharmaceuticals's earnings has grown year over year. AVIR earnings in the past year totalled -$139.49 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.